ACCEL Lite: The EARLY Trial (Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment)

<p>What is the optimal therapeutic strategy in non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in patients not pretreated with P2Y12 adenosine diphosphate receptor antagonists, and why reduce the time to invasive strategy in NSTE-ACS? In this interview, John Gorcsan, Laurent Bonello, and Arjun Majithia discuss the EARLY trial (Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment).</p>